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Abstract: Counterfeiting is a global phenomenon that poses a serious financial threat to the
pharmaceutical industry and more importantly jeopardizes public safety and security. Different
measures, including new laws and regulations, have been put in place to mitigate the threat and
tighten control in the pharmaceuticals supply chain. However, it appears that the most promising
countermeasure is track-and-trace technology such as electronic-pedigree (E-pedigree) with
Radio Frequency Identification (RFID) technology. In this study we present a framework
exploring the antecedents and consequences of RFID applications in the pharmaceutical supply
chain. The framework proposes that counterfeiting and E-pedigree regulation will drive the
implementation of RFID in the pharmaceutical supply chain, which in turn provides strategic and
operational benefits that enable competitive advantage. Meanwhile, the implementation of RFID
requires overcoming many operational, technical and financial challenges. The framework
provides a springboard that future study can explore using empirical data.
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1 Introduction
According the World Health Organization (WHO), counterfeit drugs are defined as substandard
pharmaceuticals which are mislabeled intentionally and fraudulently. Counterfeit drugs may
include products with the correct ingredients with false packaging and may involve the absence
or insufficient amount of active ingredients (WHO, 2006). In essence, counterfeit drugs are
pharmaceutical products that possess qualities below the established standards, which render
them ineffective for treatment of diseases and could be potentially hazardous or fatal to patients.
This spreading phenomenon involves both branded and generic products. In the United States
(U.S.), in 2004 the National Association of Boards of Pharmacy (NABP) created a “National
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Specified List of Susceptible Products” (NABP, 2004: see Exhibit 1 in the Appendix). These
drugs were designated and determined to be susceptible to adulteration, counterfeiting or
diversion, and could potentially pose risks to the public health (NABP, 2004). Counterfeiting is
much more widespread and can involve many drugs from different therapeutic classes. Drugs
from different classes, regardless of their prices, have been counterfeited. Expensive lifestyle
and anti-cancer drugs, antihypertensive and lipid lowering agents, antibiotics as well as drugs for
life-threatening diseases such as HIV/AIDS or tuberculosis or malaria in developing countries
were reported to be counterfeited (WHO, 2006; NABP, 2004). In addition, there have been
reported cases of counterfeits of hormones, steroids and pain killers as well as inexpensive
generic products. However, for the most part, the combination of expensive drugs and the
relative ease of access to the supply chain put the pharmaceutical industry and patients at high
risk (NABP, 2004).
In 2006, Intercontinental Marketing Services (IMS) Health identified four of the top ten
leading branded drugs in sales volume as susceptible for counterfeiting by the NABP (IMS
Health, 2007a; NABP, 2007). The cholesterol-lowering medication Lipitor had the highest sales
in 2006 and was also on the National Specified List of Susceptible Products. To put the financial
impact of counterfeiting in perspective, if Pfizer lost just one percent of Lipitor sales to
counterfeiting it would cost them 136 million U.S. dollars, which is money that cannot be used to
recoup the investment in the development of Lipitor and to develop new drugs. Different
measures, including new laws and regulations, have been put in place to mitigate the threat and
tighten control on pharmaceuticals as they travel throughout the supply chain. However, it
appears that the most promising countermeasure is establishing track-and-trace technology such
as electronic-pedigree (E-pedigree) with Radio Frequency Identification (RFID) technology.
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Radio frequency identification systems have been used in the manufacturing environment
since the early 1990s as a way to control and track products moving on assembly lines, and the
part bins that feed the line (Stall, 1993). These early manufacturing implementations of RFID
utilized proprietary systems that were internal to the organization. As RFID technology around
standardized open systems evolved and costs decreased, other RFID applications became
feasible, drawing the interest of additional supply chain entities. Industry mandates by Wal-Mart
(O’Connor, 2005) and the U.S. Department of Defense (Collins, 2004a) provided the motivation
to expand RFID systems beyond the factory walls to include suppliers, logistics providers and
customers.
Our discussion of RFID systems focuses on the use of passive, chip-based, read-write tags
which provide a ‘living history’ of the item being tracked and therefore have the potential to
increase the transparency of items moving through a manufacturing facility and the supply chain
(Li and Visich, 2006). However, this ‘living history’ is stored in a secure database, not on the
chip as will be explained in the next paragraph.
In an RFID system a unique identifier, such as an EPC or an e-Pedigree, is embedded into the
micro-chip in a tag. The tag is then attached to the item being tracked. As the item moves into
the scanning range of the reader, the reader sends out electromagnetic waves that form a
magnetic field when they ‘couple’ with the antenna on the RFID tag. The tag draws power from
the magnetic field and uses it to power the micro-chips’ circuits. The micro-chip then modulates
the signal received in accordance with its identification or programmed code and transmits or
reflects a radio frequency signal. The modulation is in turn picked up by the reader, which
decodes the information contained in the transponder, and depending upon the reader
configuration, either stores the information, acts upon it, or transmits the information to the host
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computer via the communications port (Jones et al., 2004). It is the database linked to the host
computer that records and stores the history of the tagged item. For a detailed discussion on how
RFID systems operate see Dinning and Schuster, 2003; Jones et al., 2004; Srivastava, 2004;
Angeles, 2005; or Li et al., 2006.
Because RFID tags include tiny micro-chips that can store more information compared with
bar-code technology, the U.S. Food and Drug Administration (FDA) considers RFID a more
promising technology as a means to achieve e-pedigree (FDA, 2004). E-pedigree systems
depend on technology that would carry the serialized information to automatically identify each
bottle or vial (Focinio, 2007) and RFID technology can be used to identify pharmaceuticals at the
item level. The Serial Number portion of the EPC on a 96-bit tag is reserved to identify the
unique product item and it has the capacity to uniquely identify nearly 69 billion items for a
single stock-keeping-unit (Brock, 2001). In addition, RFID tags can provide real-time
information with a capability of reading multiple items simultaneously with no direct line of
sight to reader. In contrast, bar codes have a limitation of reading one item at a time and the
scanner has to be in a direct line of sight with the bar codes, which can be labor intensive
(Wilding and Delgado, 2004).
RFID could provide benefits to all partners in the pharmaceutical supply chain, including
manufacturers, distributors, retailers and hospitals. Most importantly, patients and the public at
large will benefit from this technology. The use of RFID will improve the tracking of drugs as
they travel downstream in the supply chain, improving product visibility thereby making it easier
to detect counterfeiting and the malicious insertion of poisonous drugs by terrorists (Wicks et al.,
2006). In addition, RFID could provide customer and patient security at the point of sale or
dispensing. According to the Pharmaceutical Research and Manufacturers of America,

4

“electronic authentication at the dispensing level provides a direct means of determining in realtime whether a particular packaging unit is authentic (PhRMA, 2005).”
Regardless of increased attentions to RFID and many proposed benefits of RFID
implementation in the pharmaceutical supply chain, few studies have provided an integrated
view of RFID implementation in the pharmaceutical industry. To fill this gap, this study
developed a framework exploring the antecedents and consequences of RFID applications in the
pharmaceutical supply chain (see Figure 1). This study provides a comprehensive evaluation of
the potential and challenges of RFID and thus offers useful guidelines for pharmaceutical
companies who are interested in adopting this technology. Moreover, this study offers a
framework that future study can explore.
The paper is organized as follows. We first present our framework. Next, we discuss the
drivers of RFID implementation in the pharmaceutical supply chain, followed by a discussion of
various applications of RFID, associated benefits and the challenges of implementing RFID. We
end our paper with research implications and our concluding thoughts on RFID systems in the
pharmaceutical supply chain.
--------------------------------------------INSERT FIGURE 1 ABOUT HERE
--------------------------------------------2 Framework for RFID implementation in the pharmaceutical supply chain
Figure 1 proposes that counterfeiting and E-pedigree regulation will drive the implementation of
RFID in the pharmaceutical supply chain, which in turn provides strategic and operational
benefits. Strategic benefits include counterfeit prevention, recall precision, reimbursement
compliance, and brand protection. Operational benefits consist of ship and receive, labor and
inventory, Prescription Drug Marketing Act (PDMA) compliance and loss prevention.
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Meanwhile, the implementation of RFID requires overcoming many operational (tag positioning,
liquid and biological tagging, read rate, and interference between wireless medical devices),
technical (lack of standard for E-pedigree and inconsistent tag frequency), financial (cost of
implementation) and other challenges (privacy concern). We now discuss the drivers for RFID
implementation in the pharmaceutical supply chain.

2.1 Counterfeiting
According to IMS Health (2007b), the global pharmaceutical sales market in 2006 was estimated
to be U.S. $643 billion. The WHO has estimated counterfeit drug sales as a percentage of total
drug sales to be about 1% in industrialized nations and up to 10% in some developing countries,
which is substantial and poses a threat to the profitability of the pharmaceutical industry. It was
also predicted that counterfeit drug sales would increase by 90% from 2005, reaching about $75
billion globally in 2010 (WHO, 2006). Though the prevalence of counterfeit drugs in the U.S. is
unknown, it has become a growing problem.
In the U.S., the number of FDA counterfeit investigations has increased significantly over
recent years. The frequency of counterfeit investigations was 58 in 2004, an almost six-fold
increase from 1997 (Lutter, 2005). However, in 2005, the FDA’s Office of Criminal
Investigations (OCI) initiated 32 counterfeit drug cases, a significant decrease from the year
before. This could be in part due to an increased awareness and vigilance at all levels of the drug
distribution chain and due to increased coordination with other state and federal law-enforcement
agencies and better communication with drug manufacturers (Lutter, 2005). Or, due to the
inability of regulatory agencies and the pharmaceutical supply chain to track and trace drugs,
counterfeiters might be using new methods that are more difficult to detect.
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According to Patton (2006), the global pharmaceutical industry is heavily regulated.
However, the rules as well as prices are different from one country to another, which tends to
foster illegitimate business. In the U.S., the wholesale pharmaceutical business is primarily
controlled by three main wholesales: Cardinal Health, McKesson, and Amerisource Bergen,
which have a market share of over 90%. The rest of the market is shared by hundreds of
wholesalers that serve as legitimate businesses in moving excess inventory from large
distributors to the next customer in the supply chain. These smaller businesses increase the
complexity of the pharmaceutical supply chain which reduces visibility and creates an
opportunity for counterfeiters to enter the supply chain (Patton, 2006). In industrialized nations,
internet-based sales pose a major threat to the pharmaceutical supply chain as they provide an
easily procured source of counterfeits from different countries (WHO, 2006). In the U.S., the
illegal importation of drugs through internet sales from Canada or Mexico poses a threat to
patients and the public who seek cheaper and unauthorized drugs with unknown origins.

2.2 Government regulation and E-Pedigree
In the U.S., the pharmaceutical supply chain stakeholders as well as U.S. state and federal
officials have recently collaborated on establishing countermeasures to mitigate the risk of
counterfeiting and tighten control on pharmaceuticals to increase security and protect the public.
The most promising countermeasure is establishing track-and-trace technology such as
electronic-pedigree (e-Pedigree) with RFID technology.
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2.2.1 U.S Counter Drug Task Force
Counterfeiting seems to be the greatest in regions or countries with weak legal and regulatory
structure (WHO, 2006). In the U.S., federal and state law enforcement agencies and in
collaboration with all stakeholders in the pharmaceutical industry are devoting more efforts and
recourses to combat counterfeiting. The U.S. Counter Drug Task Force has outlined
countermeasures to protect the pharmaceutical supply chain such as the adoption and
enforcement of strong laws and regulations, increasing criminal penalties to deter counterfeiting,
securing business practices, implementing new technologies including “track and trace” and
authentication of drugs in the supply chain, educating the public and health care professionals,
and developing effective methods of reporting counterfeit pharmaceuticals (FDA, 2004).

2.2.2 U.S. federal laws and the Prescription Drug Marketing Act
On the federal level, the Prescription Drug Marketing Act of 1987 (PDMA), as modified by the
Prescription Drug Amendments of 1992, has mandated requirements that every drug must have a
full pedigree. A drug pedigree is a statement of origin, which provides the chain of custody of
drugs as they are purchased, sold, or traded. This was needed as a method of accounting for the
origin of pharmaceuticals and a verification of legitimacy. All involved parties names and
addresses, and dates of transactions have to be identified and included for each sale of a drug.
The main purpose of the PDMA is to tighten security and address problems of drug
counterfeiting in the pharmaceutical supply chain (FDA, 1987; FDA, 1992). In essence, the
PDMA set the guidelines to ensure the safety and authenticity of drugs as they move throughout
the pharmaceutical supply chain.
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The PDMA and existing regulations do not require any particular technology for pedigrees
such as bar-code, RFID or other technologies. However, the FDA made a clear statement in its
February, 2004 Combating Counterfeiting Drugs report that RFID represents one of the most
important tools to help improve the safety of the drug supply chain (FDA, 2004). Furthermore,
the FDA had requested the pharmaceutical industry to pilot track-and-trace solutions based on
RFID and related technologies such as mass serialization and electronic pedigrees (E-pedigree)
by the end of 2007. Mass serialization involves assigning an electronic product code (EPC) to
each pallet, case, and individual package of drugs, thereby providing an E-pedigree that can be
tracked from manufacturing to dispensing. And, the FDA has set January 2010 as the deadline
for the implementation of a pedigree system (Swedberg, 2008). In addition, industry
associations such as the Healthcare Distribution Management Association (HDMA) have
published position statements advocating the accelerated adoption of electronic track and trace
using EPC tagging. Specifically, the HDMA advocated the adoption at the case level by the end
of 2005 and at the selling unit level by 2007. At the same time, RFID standards groups such as
EPCglobal were exploring what standards and new practices need to be established to adopt
electronic track-and-trace technologies throughout the supply chain (FDA, 2004). More
recently, EPCglobal ratified a new E-pedigree standard, which is designed to aid companies in
complying with mass serialization and E-pedigree regulations (EPCglobal, 2007).

2.2.3 U.S. state laws
On the state level, stronger requirements to safeguard the drug supply chain have been adopted
by some states such as Florida and California. Florida has taken the lead by passing legislation
that pharmaceutical product tracking and tracing should be embraced through the accumulation
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of a paper-based product pedigree, detailing specifics about the supply chain history of each drug
shipment. In 2006, Florida expanded its requirement for paper-based pedigrees as a first step
and subsequently established a system of E-pedigree verification utilizing electronic data
interchange (EDI) (Koroneos, 2007). Thus the system that has been established by Florida has
been applicable to both paper-based and E-pedigree in the pharmaceutical supply chain. More
recently, Florida has pushed for an electronic signature and verification version for pedigrees
(Farber, 2007). In addition, California, Nevada and Virginia have also adopted laws to mandate
some sort of pedigree for each drug sold in these states, which would require chain of custody
from manufacturing to dispensing (Wasserman, 2005). California enacted an E-pedigree law
that would mandate pharmaceutical companies, wholesalers, and hospitals to use electronic
traceability for pharmaceuticals by early 2009. However, the law did not specify the use of
RFID tags (Farber, 2007). Wholesalers in California opted for the more advanced electronic
product code information system (EPCIS), which relies on web based connections rather than a
single point connection such as EDI (Koroneos, 2007). Recently, due to industry pressure, the
California State Board of Pharmacy decided to delay implementation of its E-pedigree
requirement until 2011 (Swedberg, 2008). In addition to these efforts, the NABP made some
efforts to revise the Model Rules, in order to strengthen the requirements for wholesalers as well
as establish stricter measures to ensure and protect the pharmaceutical supply chain (FDA,
2004).

2.2.4 European regulatory views
Currently there are no regulations in the European Union (EU) requiring the use of e-pedigrees
to track pharmaceuticals. A 2005 European Federation of Pharmaceutical Industries and
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Associations report pronounced RFID as too expensive for item level drug tracking until at least
2010, recommending 2D barcodes for mass serialization in the interim (Harrop, 2007). The
Italian government has proposed an initiative to require the use of dual bar coding (called
bollino) to facilitate the reporting of sales data within 24 hours of any transaction along the
supply chain. The regulation is meeting resistance from the Italian pharmaceutical industry
because the use of bollino would slow productivity since high-volume scanners have not yet
been developed (Wasserman, 2005). The lack of regulations and guidance from EU legislators
means the European pharmaceutical industry will have to take the lead to reduce counterfeiting
and protect the public safety.

3 RFID implementation and benefits in the pharmaceutical industry
Manufacturers, wholesalers and retailers have recently conducted pilot programs and undertaken
major initiatives to evaluate benefits and the costs associated with RFID technology in the
pharmaceutical supply chain. Figure 2 shows the supply chain for drugs in the United States.
Note that direct-to-consumer web sales from foreign based firms are not part of this supply
chain.
The potential benefits of adopting RFID technology to achieve e-pedigree in the
pharmaceutical supply chain can be divided into strategic and operational benefits (see Table 1).
For manufacturers, RFID technology could offer brand identity protection, reduce the risk of
product tampering, decrease losses of theft and counterfeiting, and enhance product cycle
information. For wholesalers, there will be increased efficiency in managing logistics and
inventory. Retailers will increase patient confidence in their products, increase accuracy in their
fill rate, and improve visibility and inventory management (Gebhart, 2007; Wicks et al, 2006;
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Anonymous, 2004). The following section will discuss RFID initiatives and corresponding
benefits from manufacturers, distributors/wholesalers, drugstore and retailers, and hospitals and
health care providers respectively.
--------------------------------------------INSERT FIGURE 2 ABOUT HERE
----------------------------------------------------------------------------------------INSERT TABLE 1 ABOUT HERE
--------------------------------------------3.1 RFID initiatives from manufacturers
Wal-Mart, which has a pharmacy division and has been the leader in implementing RFID, as
well as the U.S. Department of Defense (DOD) have ordered all their pharmaceutical suppliers to
tag their products (Wasserman, 2005). Major initiatives to deploy RFID technology began early
by key players in the pharmaceutical industry such as Pfizer, Purdue, Merck, Novartis and
AstraZeneca.
In early 2006, Pfizer began to place RFID tags on all units of Viagra (erectile dysfunction
drug) sold in the U.S., including bottles, cases, and pallets. The drug's popularity and high
volume sales (over $1.68 billion & $850 million in 2004 and 2005, respectively) made it an
attractive target of counterfeiters and therefore a prime opportunity for RFID-based counterfeit
prevention (Wasserman, 2005; IMS Health, 2006). Pfizer focused on EPC authentication as a
mean of deterring counterfeiting, which is a system that is not a track-and-trace solution nor is an
e-pedigree system. Companies such as Purdue, GlaxoSmithKline, Merck and Novartis as well as
others are running pilot programs to tag individual drug items in order to detect dispensing errors
and counterfeiting before reaching patients. Purdue Pharma was one of the first in the industry
to begin individual RFID tagging of Oxycontin (schedule II narcotic) bottles (Wasserman, 2005).
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AstraZeneca also took a proactive approach to RFID by participating in the standards setting
process, led through EPCglobal, and through the planned execution of a pilot in 2006. The pilot
study involved using both RFID tags and bar codes to provide serialization of individual items
and cases to protect its widely sold drug Nexium from tampering and counterfeiting
(Demetrakakes, 2005; Lewcock, 2007). In 2006, GlaxoSmithKline attached RFID tags to all
bottles of its HIV drug Trizivir (abacavir/lamivudine/zidovudine) distributed in the U.S. as part
of a patient safety pilot project (Anonymous, 2006). The company chose Trizivir for the pilot
because it was listed on NABP's list of the most susceptible drugs to counterfeiting and diversion
(see Exhibit 1 in the Appendix). Many of the results of these pilot studies were shared with the
FDA, but have not been shared publicly or published.

3.2 RFID initiatives from distributors and wholesalers
After drugs are manufactured and tagged, they are moved downstream to wholesalers and then to
retailers’ distribution centers in pallets and cases (see Figure 2). In turn, most of wholesalers or
retailers distribution centers ship small quantities of different drugs to hospitals or retailers by
bottles grouped in totes. As required by state laws, distributors and wholesalers are required to
provide some type of pedigree documenting the chain of custody, lot number and expiration date
of each drug sold. Cardinal Health, one of the largest U.S. wholesalers, recently concluded an
RFID pilot program, which included tracking pharmaceuticals at all levels. Their pilot program
revealed that the technology read rate is very reliable at the item level. In their pilot, they utilized
EPC Gen 2 UHF (Ultra High Frequency) tags to track pallets, cases and individual items, and
they attained a read rate of more than 99% (Bacheldor, 2006). Early in 2007, Cardinal Health
announced it would integrate RFID technology into its pharmaceutical distribution center
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operation at Sacramento, CA. by fall of 2007. This is in preparation for California’s pedigree
mandate that will require all drugs distributed in the state to be tracked and traced at each step
throughout the supply chain (Cardinal Health, 2007). Distributors have been trying to overcome
some technical and business process issues (discussed later) before the widespread adoption and
implementation of RFID.

3.3 RFID initiatives from drug stores and retailers
Retailers embarked on RFID technology in order to enhance compliance with the pedigree
regulations. In an early pilot study, dubbed Project Jumpstart, manufacturers including Abbott
Laboratories, Pfizer, Johnson & Johnson and Procter & Gamble shipped bottles of RFID tagged
pills to distributors McKesson Corp. and Cardinal Health who then shipped to CVS and Rite Aid
retail pharmacies (Whiting, 2004). The results showed that RFID could help satisfy both
regulatory and retailer requirements, increase product security and consumer safety, enhance
order accuracy and labor productivity as well as increase efficiency, and speed of recalls and
returns. These findings were based on shipping, tracking and tracing of nearly 13,500 packages
of pharmaceuticals over an eight week time frame. Thus, this project created the initial steps
towards innovative approaches to address key issues such as mitigating the risk of counterfeiting
and increasing supply chain visibility within each organization and across partners in the
pharmaceutical supply chain to comply with the new regulations. The group also worked with
the FDA’s Anti-Counterfeiting Task Force to improve the pharmaceutical supply chain integrity,
which is a high priority of the FDA. Furthermore, HDMA and the National Association of Chain
Drug Stores (NACDS) were involved with this effort and provided the rest of their members
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with information and educational material based on the results . However, these tests did not
involve consumers (Anonymous, 2004).

3.4 RFID initiatives from hospitals and health care providers
In the healthcare system, there is an increasing interest in reducing the high rate of medical errors
in order to improve patient safety through the utilization of RFID technology. Additionally,
RFID could be utilized for inventory control, asset management, as well as to capture and
provide accurate data about patients including identification and movement. Many hospitals use
RFID to identify infants and match them with their parents (Ashar and Ferriter, 2007). RFID
could also be used for tracking and matching blood for transfusions, and combating the
counterfeiting of medical products (Wicks et al., 2006). More importantly, it is becoming part of
electronic medical records, as information is stored on the RFID tag, which could accompany
patients. In a recent pilot study, RFID was utilized to ensure the quality, security and accuracy
of prescribing and administering complex and critical drugs such as chemotherapeutic agents
(Spahni et al., 2006). Making use of all traceability data acquired from prescription to
preparation to administration validate in real time that the right drug and dose are being given to
the right patient at the right time, and can also record who handled the drug. Furthermore,
potential long-term applications of RFID are to capture data generated from medical devices
such arterial blood pressure and other cardiac monitoring parameters and making them available
as part of the electronic medical records (Ashar and Ferriter, 2007).
RFID was also tested by the U.S. Navy to track and provide information about wounded
soldiers in the battlefield (Schwartz, 2004). A similar system was also piloted in a hospital in an
operational environment in Iraq, which resulted in the accurate documentation of casualties,
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increased awareness of patient needs, and also maximized resources (Collins, 2004b). This
system can be applied to an emergency response system, where speed and accuracy of treatment
are critical to the patient’s health (Wicks et al., 2006).

4 Challenges with RFID adoption in the pharmaceutical supply chain
Pharmaceutical companies are faced with many operational, technical and financial challenges in
adopting RFID (see Figure 1).

4.1 Operational challenges
Companies are required to label not only pallets and cases but also each drug bottle to create a
system that will allow for authentication. It becomes even more challenging to decide where to
position the RFID tag on the bottle in order to be read within a case or pallet. Additionally,
tagging must be automated because of the huge volume of bottles that move through the
packaging line. There are also concerns about the speed and accuracy of electronic devices and
systems. Failure read rate can happen especially with vials made of metals and or containing
liquids (Patton, 2006). Tagging liquids and biological products will be even more challenging
due to space issues on the exterior of bottles and vials and also due to the questionable effect of
radio waves on these products. Studies have shown that radio waves do not affect drugs in solid
form, however, there are no studies published to date that look into the effect of radio waves
from RFID tags on the stability and potency of liquids and biological products (Patton, 2006;
Wasserman, 2005). In hospitals, RFID technology has the potential to interfere with wireless
communications of medical devices, especially if the same frequency is used (Ashar and Ferriter,
2007). In January of 2007 the FDA issued a draft guidance report on the design, development
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and testing of radio frequency wireless technology in medical devices. The focus of the report is
to protect patients and operators from adverse effects caused by interference between wireless
medical devices (FDA, 2007).

4.2 Technical challenges
Technical issues include the lack of consensus on standards for e-pedigree fields and formats, data

systems, frequency and international transmission systems as well as software and hardware
specifications (FDA, 2006). However, in January of 2007, EPCglobal ratified the new epedigree document standard, which should help companies to serialize products using EPC
technology and thus comply with a wide variety of pedigree regulations. Establishing e-pedigree
standards should also resolve the interoperability issue of exchanging document-based pedigrees.
Moreover, EPCglobal has started working on developing a full track and trace system based on
the EPC Information Services (EPCIS) standard, allowing the information to be shared upstream
and downstream in the pharmaceutical supply chain (Harrison, 2007).
Unlike the U.S. and Europe, where the EPCglobal is the standard, Asian countries, including
China, use their own classification systems. China supports the National Product Code (NPC),
which is its own EPC-classification system for labeling products. Japan also uses a different
standard, which does not communicate with the standard set by EPCglobal. Thus,
standardization on a global level is still challenging and might take several years to overcome
(Fish and Forrest, 2007).
Tag frequency is another technical issue that is not consistent worldwide. Both Europe and
the U.S. use UHF in the range from 868 MHz to 915 MHz, respectively, while Japan uses UHF
for RFID at a higher frequency than 915 MHz (Fish and Forrest, 2007). China has not accepted
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UHF at these frequencies because they are designated for telecommunications, radio
broadcasting and aerospace (Hotchkiss, 2005). Instead, China’s Ministry of Information
industries has approved bandwidth in the 840.25 to 844.75 MHz and 920.25 to 924.75 MHz
ranges for passive tags (Swedberg, 2007). These inconsistencies among different countries could
increase the cost of implementation of RFID due to an increase in reader complexity and other
hardware components to handle different frequencies.

4.3 Financial challenges
Though RFID technology can improve efficiency in the supply chain, cost becomes an issue,
especially when tagging low cost items. Therefore, it would be prudent to apply such technology
to high priced drugs to reduce cost in relative terms. Pfizer spent $5 million just to set up the
tracking system for Viagra (Gebhart, 2007). A study by HDMA demonstrated that the startup
cost of RFID for large pharmaceutical manufacturers and distributors would be $15-20 and $920 million, respectively. However, it was also estimated that on an annual basis pharmaceutical
manufacturers and distributors would gain from $500 million to $1 billion and $200-400 million,
respectively, with wide adoption of RFID technologies (Wasserman, 2005). Tag costs are
dropping and are highly dependent on volumes purchased and prices can vary from one country
to another. For example, passive tags in the U.S cost about 7 cents versus 10 cents in Europe and
up to 30 cents in Asia (Fish and Forrest, 2007). It is clear that more studies are needed to fully
evaluate the business case for RFID, beyond the safety and compliance issues.
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4.4 Other challenges
Privacy and data sharing are major concerns, especially for patients. Health care providers and
pharmacists need to be aware of and be compliant with the U.S. Department of Human and
Health Services Insurance Portability and Accountability Act (HIPAA) to safeguard patients’
medical information (Wicks et al., 2006). The American Civil Liberties Union and Consumers
Against Supermarket Privacy Invasion and Numbering (CASPIAN) have raised concerns over
tracking patients’ medications and invading their privacy through the use of RFID in the retail
setting (EPIC, 2007). Currently this is not an issue at the retail level because RFID tags are
placed on large bottles that retailers buy and not on the individual containers that are dispensed
to customers (FDA, 2006). Additionally, security measures can be applied to the RFID tags to
prevent the accessibility of confidential patient information (Wicks et al., 2006).
There are also major concerns about the ownership of the confidentiality of the business
transaction data as it travels through the supply chain. It is critical for partners in the
pharmaceutical supply chain to able to share information in order to ensure a successful
transmission of e-pedigree throughout the supply chain (Forcinio, 2007). Moreover, it is the
consensus of the FDA that it is essential for each partner in the supply chain to have access to the
pedigree information, starting from the original manufacturer. The FDA also wants pedigree
access in order to monitor suspicious or illegal activity (FDA, 2006).

5 Research limitations, implications and future research
This review of RFID and the pharmaceutical supply chain provides a comprehensive evaluation
of the potential of RFID among all stakeholders in the supply chain. It provides practitioners
information about RFID technology, and its utilization and potential benefits in the
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pharmaceutical supply chain and healthcare system. Additionally, it increases the level of
awareness about the issues facing the pharmaceutical supply chain such as: the scope of
counterfeit pharmaceuticals and the importance of increased vigilance and tighter control on
pharmaceuticals as they travel throughout the supply chain; the legal and regulatory mandates;
and the implementation challenges with RFID technology, including the technical, security and
privacy hurdles. We attempted to present a balanced and comprehensive view of the issues.
However, we had to rely primarily on non-peer reviewed literature due to the lack of peer
reviewed publications related to this topic, which could have confounded our conclusions and
presented some biases towards RFID. And, most RFID pilot study results were shared privately
with stakeholders and were not made available to the public, especially the cost-benefit analysis.
Beyond the mandates, it is clear that more controlled studies are needed to fully examine the
cost-benefit ratio and the return on investment of RFID at all levels in the pharmaceutical supply
chain. It is also crucial for the results of studies to be shared with all stakeholders, including the
public.
We provide a framework (see Figure 1) that future study can use to create a conceptual
model and theoretical propositions that can be investigated using field research and empirical
data. This model could also posit how implementation of RFID might lead to competitive
advantage. Another study could investigate how RFID can mitigate the risks to the
pharmaceutical supply chain. Research could also focus on the level of implementation and how
the benefits change as RFID is deployed. We hypothesize that the benefits of RFID will increase
as RFID is implemented at more points along the pharmaceutical supply chain shown in Figure
2. And, that the greatest benefits will occur when RFID is deployed in the entire supply network.
Such studies can deepen our understanding of RFID adoption in the pharmaceutical supply chain
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and offer empirical justification for the benefits and challenges discussed in the non-peer
reviewed literature.

6 Conclusion
The safety and security of the pharmaceutical supply chain hinges on the visibility and
accountability of the drugs as they travel downstream in the supply chain. Compliance with
PDMA is essential and the supply chain will have to capitalize on the advances of electronic
track-and-trace based on RFID, as it appears to be the most promising technology to create epedigree. However, RFID technology is still emerging and the pharmaceutical supply chain
needs to overcome the associated challenges to fully realize the wide range of benefits associated
with the implementation of RFID, beyond the mandates. It is also critical to conduct more
studies to justify the business case for RFID, since RFID technology provides an opportunity to
improve supply chain efficiency and more importantly, public safety.

Initial submission February, 2008. Accepted in February, 2009 after two revisions.
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Figure 1. RFID Implementation in the Pharmaceutical Supply Chain
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Figure 2 Diagram of the Flow of Drugs in Pharmaceutical Supply Chain
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Table 1. Strategic and Operational Benefits of RFID and e-Pedigree
Manufacturers Distributors/ Retailers
Wholesalers
Strategic
Counterfeit
Prevention
Recall
Precision

Reimbursement
Compliance

Brand
Protection

Operational
Ship & Receive

Labor &
Inventory
PDMA
Compliance
Loss
Prevention

Prevention of
tainted raw
materials
Track and trace
raw materials from
receiving to
distributor and
drugs from
distributors
N/A

Prevention of
tainted bulk
containers
Track & trace
drugs from
manufactures to
retailers and
back

Protects brand
image, safety,
reputation &
profitability

Promotes safety

Provides faster and
accurate shipping
& receiving

Provides faster
and accurate
shipping &
receiving

Decreased costs of
labor and
inventory
Increased
compliance

Decreased costs
of labor and
inventory
Increased
compliance

Increased security
of raw materials,
work-in-process
and finished goods
in storage

Increased
security as
product is
transported
downstream and
is stored in the
warehouse

N/A

Hospitals

Public

Track and trace
drugs from
distributors to
patients and
back

Prevention of
tainted
bottles/vials
Track and trace
drugs from
distributors to
patients and
back

Increased
awareness and
safety measures
Increased
safety by
alerting
patients of
tainted drugs

Increased
accuracy of
reimbursements
and decreased
paperwork &
errors
Promotes
Safety and
increases
consumer
confidence

Increased
accuracy of
reimbursements
and decreased
paperwork &
errors
Promotes
Safety and
increases
consumer
confidence

Increased
accuracy of
reimbursements
and decreased
paperwork &
errors
Promotes
Safety and
increases
Consumer
confidence

Increased
accuracy of fill
rate and reduce
medication
errors
Decreased
costs of labor
and inventory
Increased
compliance

Increased
accuracy of fill
rate and reduce
medication
errors
Decreased
costs of labor
and inventory
Increased
compliance

Increased
safety and
decrease
adverse events

Increased
security against
employee theft
and customer
shoplifting

Increased
security against
employee theft

Decreased
prices

Prevention of
tainted bottles

Decreased
prices
Increased
safety
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Appendix
Exhibit 1. The National Specified List of Susceptible Products (NABP, 2004)
1. Combivir® (lamivudine/zidovudine)
2. Crixivan® (indinavir)
3. Diflucan® (fluconazole)
4. Epivir® (lamivudine)
5. Epogen® (epoetin alfa)
6. Gamimune® (globulin, immune)
7. Gammagard® (globulin, immune)
8. Immune globulin
9. Lamisil® (terbinafine)
10. Lipitor® (atorvastatin)
11. Lupron® (leuprolide)
12. Neupogen® (filgrastim)
13. Nutropin AQ® (somatropin, E-coli derived)
14. Panglobulin® (globulin, immune)
15. Procrit® (epoetin alfa)
16. Retrovir® (zidovudine)
17. Risperdal® (risperidone)
18. Rocephin® (ceftriaxone)
19. Serostim® (somatropin, mannalian derived)
20. Sustiva® (efavirenz)
21. Trizivir® (abacavir/lamivudine/zidovudine)
22. Venoglobulin® (globulin, immune)
23. Viagra® (sildenafil)
24. Videx® (didanosine)
25. Viracept® (nelfinavir)
26. Viramune® (nevirapine)
27. Zerit® (stavudine)
28. Ziagen® (abacavir)
29. Zocor® (simvastatin)
30. Zofran® (ondansetron)
31. Zoladex® (goserelin)
32. Zyprexa® (olanzapine)
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